How Can Advanced Imaging Be Used to Mitigate Potential Breast Cancer Overdiagnosis?

被引:22
作者
Rahbar, Habib [1 ]
McDonald, Elizabeth S. [2 ]
Lee, Janie M. [1 ,4 ]
Partridge, Savannah C. [1 ]
Lee, Christoph I. [1 ,3 ,4 ]
机构
[1] Univ Washington, Sch Med, Dept Radiol, 825 Eastlake Ave East,G3-200, Seattle, WA 98109 USA
[2] Univ Penn, Dept Radiol, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98109 USA
[4] Hutchinson Inst Canc Outcomes Res, Seattle, WA 98109 USA
基金
美国国家卫生研究院;
关键词
Overdiagnosis; breast cancer; breast imaging; screening risks; CARCINOMA IN-SITU; CONTRAST-ENHANCED MRI; LOCAL RECURRENCE; SCREENING MAMMOGRAPHY; RISK; DIAGNOSIS; WOMEN; EXPRESSION; DIFFUSION; GRADE;
D O I
10.1016/j.acra.2016.02.008
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Radiologists, as administrators and interpreters of screening mammography, are considered by some to be major contributors to the potential harms of screening, including overdiagnosis and overtreatment. In this article, we outline current efforts within the breast imaging community toward mitigating screening harms, including the widespread adoption of tomosynthesis and potentially adjusting screening frequency and thresholds for image-guided breast biopsy. However, the emerging field of breast radiomics may offer the greatest promise for reducing overdiagnosis by identifying imaging-based biomarkers strongly associated with tumor biology, and therefore helping prevent the harms of unnecessary treatment for indolent cancers.
引用
收藏
页码:768 / 773
页数:6
相关论文
共 50 条
[41]   Can Molecular Subtyping Be Used to Guide Metastatic Screening in Breast Cancer? [J].
O'Connor, Siobhan M. ;
Lawton, Thomas J. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2015, 143 (04) :468-470
[42]   Minimal Residual Disease in Breast Cancer: Can It Be Used as a Prognostic Marker? [J].
T. Liakakos .
Annals of Surgical Oncology, 2008, 15 :1793-1794
[43]   Can preoperative lymphoscintigraphy be used as a guide in treatment planning of breast cancer? [J].
Mudun, A ;
Aslay, I ;
Aygen, M ;
Muslumanoglu, M ;
Bozfakioglu, Y ;
Cantez, S .
CLINICAL NUCLEAR MEDICINE, 2001, 26 (05) :405-411
[44]   Neoadjuvant chemotherapy in breast cancer: Which diagnostic procedures can be used? [J].
Loehberg, CR ;
Lux, MP ;
Ackermann, S ;
Poehls, UG ;
Bani, MR ;
Schulz-Wendtland, R ;
Papadopoulos, T ;
Schmucker, M ;
Beckmann, MW ;
Fasching, PA .
ANTICANCER RESEARCH, 2005, 25 (3C) :2519-2525
[45]   How valuable can proteogenomics be in clinical breast cancer research? [J].
Tran-Huynh, Anh M. ;
Holt, Matthew V. ;
Anurag, Meenakshi .
EXPERT REVIEW OF PROTEOMICS, 2023, 20 (1-3) :1-4
[46]   How can biosimilars change the trajectory of breast cancer therapy? [J].
Trapani, Dario ;
Curigliano, Giuseppe .
EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (05) :325-328
[47]   How Radiomics Can Improve Breast Cancer Diagnosis and Treatment [J].
Pesapane, Filippo ;
De Marco, Paolo ;
Rapino, Anna ;
Lombardo, Eleonora ;
Nicosia, Luca ;
Tantrige, Priyan ;
Rotili, Anna ;
Bozzini, Anna Carla ;
Penco, Silvia ;
Dominelli, Valeria ;
Trentin, Chiara ;
Ferrari, Federica ;
Farina, Mariagiorgia ;
Meneghetti, Lorenza ;
Latronico, Antuono ;
Abbate, Francesca ;
Origgi, Daniela ;
Carrafiello, Gianpaolo ;
Cassano, Enrico .
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (04)
[48]   Normalized Comparison of Cancer Detection Rates in Contemporary Breast Imaging Technologies Used in Dense-Breast Supplemental Screening [J].
Tornai, Martin P. ;
Hugg, James W. ;
Patt, Bradley E. ;
Chen, Chin-Tu ;
Santos, Eduardo A. ;
Covington, Matthew F. .
17TH INTERNATIONAL WORKSHOP ON BREAST IMAGING, IWBI 2024, 2024, 13174
[49]   Advanced breast cancer: New imaging techniques for detection of metastases [J].
Helmut Schoellnast ;
Christian Gstettner .
memo - Magazine of European Medical Oncology, 2012, 5 (2) :129-133
[50]   Breast Cancer Demographics, Types and Management Pathways: Can Western Algorithms be Optimally used in Eastern Countries? [J].
Chakraborty, S. ;
Wadasadawala, T. ;
Ahmed, R. ;
Coles, C. ;
Chatterjee, S. .
CLINICAL ONCOLOGY, 2019, 31 (08) :502-509